Search

Your search keyword '"Valk, M J M"' showing total 6 results
Start Over Author "Valk, M J M"
6 results on '"Valk, M J M"'

2. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study

Author

Fernandez, L. M., Sao Juliao, G. P., Figueiredo, N. L., Beets, G. L., van der Valk, M. J. M., Bahadoer, R. R., Hilling, D. E., Meershoek-Klein Kranenbarg, E., Roodvoets, A. G. H., Renehan, A. G., van de Velde, C. J. H., Habr-Gama, A., Perez, R. O., Abdelrazeq, A., Asoglu, O., Barroca, R., Beveridge, J., Bhowmick, A., Blower, A., Braun, M., Bujko, K., Carter, P., Carvalho, C., Coco, C., Cunningham, C., D'Hoore, A., Dimofte, G., Ding, P., Duff, S., Dwyer, S. T., Epstein, J., Evans, D., Fulford, P., Gaertner, W., Gerard, J. -P., Gollins, S., Harris, R., Harrison, J., Heat, J., Hill, J., Hobbiss, J., Huertas, E., Huq, Z., Iseas, S., Jakobsen, A., Jones, D., Jones, L., Khan, U., Kushwaha, R., Lees, N., Linn, T. Y., Loganathan, S., Lopez Campos, F., Madoff, R., Mamedli, Z. Z., Martling, A., Matzel, K. E., Melenhorst, J., Mitchell, P., Murad-Regadas, S. M., O'Dwyer, S. T., Pairola, A., Paraoan, M., Pares, O., Peeters, K. C. M. J., Pettit, S. H., Pranesh, N., Rajaganeshan, R., Ravi, S., Rawat, S., Richards, D., Riyad, K., Rossi, G., Rutten, H. J. T., Saeed, M., Salaman, J., Sanchez Loria, F., Van der Sande, M. E., Santiago, I., Selvasekar, C., Siddiqui, K. H., Smart, C., Solkar, M. H., Sun Myint, A., Taylor, B., Telford, K., Scott, N., Vaccaro, C. A., Vailati, B. B., Verberne, C., Vieira, P., Vimalchandran, D., Ward, S., Wilson, M. S., Winter, D. C., Witjes, C., Wolthuis, A. M., Zhang, J., Zhang, Z., Coco C. (ORCID:0000-0002-4713-7093), Fernandez, L. M., Sao Juliao, G. P., Figueiredo, N. L., Beets, G. L., van der Valk, M. J. M., Bahadoer, R. R., Hilling, D. E., Meershoek-Klein Kranenbarg, E., Roodvoets, A. G. H., Renehan, A. G., van de Velde, C. J. H., Habr-Gama, A., Perez, R. O., Abdelrazeq, A., Asoglu, O., Barroca, R., Beveridge, J., Bhowmick, A., Blower, A., Braun, M., Bujko, K., Carter, P., Carvalho, C., Coco, C., Cunningham, C., D'Hoore, A., Dimofte, G., Ding, P., Duff, S., Dwyer, S. T., Epstein, J., Evans, D., Fulford, P., Gaertner, W., Gerard, J. -P., Gollins, S., Harris, R., Harrison, J., Heat, J., Hill, J., Hobbiss, J., Huertas, E., Huq, Z., Iseas, S., Jakobsen, A., Jones, D., Jones, L., Khan, U., Kushwaha, R., Lees, N., Linn, T. Y., Loganathan, S., Lopez Campos, F., Madoff, R., Mamedli, Z. Z., Martling, A., Matzel, K. E., Melenhorst, J., Mitchell, P., Murad-Regadas, S. M., O'Dwyer, S. T., Pairola, A., Paraoan, M., Pares, O., Peeters, K. C. M. J., Pettit, S. H., Pranesh, N., Rajaganeshan, R., Ravi, S., Rawat, S., Richards, D., Riyad, K., Rossi, G., Rutten, H. J. T., Saeed, M., Salaman, J., Sanchez Loria, F., Van der Sande, M. E., Santiago, I., Selvasekar, C., Siddiqui, K. H., Smart, C., Solkar, M. H., Sun Myint, A., Taylor, B., Telford, K., Scott, N., Vaccaro, C. A., Vailati, B. B., Verberne, C., Vieira, P., Vimalchandran, D., Ward, S., Wilson, M. S., Winter, D. C., Witjes, C., Wolthuis, A. M., Zhang, J., Zhang, Z., and Coco C. (ORCID:0000-0002-4713-7093)

Abstract

Background: Watch and wait is a novel management strategy in patients with rectal cancer who have a clinical complete response after neoadjuvant chemoradiotherapy. Surveillance of these patients is generally intensive, because local regrowth (with the potential for salvage) occurs in 25% of patients, and distant metastases occur in 10% of patients. It is unclear for how long these patients should be followed up. To address this issue, we did conditional survival modelling using the International Watch & Wait Database (IWWD), which is a large-scale registry of patients with a clinical complete response after neoadjuvant chemotherapy who have been managed by a watch-and-wait strategy. Methods: We did a retrospective, multicentre registry study using a dataset from the IWWD, which includes data from 47 clinics across 15 countries. We selected patients (aged ≥18 years) with rectal cancer who had a clinical complete response after neoadjuvant chemotherapy, and who were subsequently managed by a watch-and-wait strategy between Nov 25, 1991, and Dec 31, 2015. Patients who had not achieved a clinical complete response or who had undergone any surgical procedure were excluded. The criteria used for defining a clinical complete response and the specific surveillance strategies were at the discretion of each participating centre. We used conditional survival modelling to estimate the probability of patients remaining free of local regrowth or distant metastasis for an additional 2 years after sustaining a clinical complete response or being distant metastasis-free for 1, 3, and 5 years from the date of the decision to commence watch and wait. The primary outcomes were conditional local regrowth-free survival at 3 years, and conditional distant metastasis-free survival at 5 years. Findings: We identified 793 patients in the IWWD with clinical complete response who had been managed by a watch-and-wait strategy. Median follow-up was 55·2 months (IQR 36·0–75·6). The probabilit

Published
2021

3. Training general practitioners to improve evidence-based drug treatment of patients with heart failure: a cluster randomised controlled trial

Author

HAG Hart- Vaatziekten, Directie Raad van Bestuur, Circulatory Health, Planningssecretariaat HCK, Biostatistiek Onderzoek, Other research (not in main researchprogram), HAG Infectieziekten, JC onderzoeksprogramma Cardiovascular Health, Valk, M J M, Hoes, A W, Mosterd, A, Landman, M A, Zuithoff, N P A, Broekhuizen, B D L, Rutten, F H, HAG Hart- Vaatziekten, Directie Raad van Bestuur, Circulatory Health, Planningssecretariaat HCK, Biostatistiek Onderzoek, Other research (not in main researchprogram), HAG Infectieziekten, JC onderzoeksprogramma Cardiovascular Health, Valk, M J M, Hoes, A W, Mosterd, A, Landman, M A, Zuithoff, N P A, Broekhuizen, B D L, and Rutten, F H

Published
2020

4. Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer

Author

Ogura, Atsushi, Ogura, Atsushi, Konishi, Tsuyoshi, Cunningham, Chris, Garcia-Aguilar, Julio, Iversen, Henrik, Toda, Shigeo, Lee, In Kyu, Lee, Hong Xiang, Uehara, Keisuke, Lee, Peter, Putter, Hein, van de Velde, Cornelis J. H., Beets, Geerard L., Rutten, Harm J. T., Kusters, Miranda, Aalbers, A. G. J., Aiba, T., Akiyoshi, T., Beets-Tan, R. G. H., Betts, M., Blazic, I. M., Brown, K. G., Campbell, N., Choi, M. H., Gollub, M. J., Hanaoka, Y., Kim, M. K., Meershoek-Klein-Kranenbarg, E., Kuroyanagi, H., Maas, M., Martling, A., Moore, J., Nieuwenhuijzen, G. A., Oh, S. N., Roodbeen, S., Sammour, T., Schaap, D., Solomon, M. J., Thomas, M., Tomizawa, K., van der Sande, M. E., Suzuki, C., van der Valk, M. J. M., Wells, T., Won, D. D., Lateral Node Study Consortium, Ogura, Atsushi, Ogura, Atsushi, Konishi, Tsuyoshi, Cunningham, Chris, Garcia-Aguilar, Julio, Iversen, Henrik, Toda, Shigeo, Lee, In Kyu, Lee, Hong Xiang, Uehara, Keisuke, Lee, Peter, Putter, Hein, van de Velde, Cornelis J. H., Beets, Geerard L., Rutten, Harm J. T., Kusters, Miranda, Aalbers, A. G. J., Aiba, T., Akiyoshi, T., Beets-Tan, R. G. H., Betts, M., Blazic, I. M., Brown, K. G., Campbell, N., Choi, M. H., Gollub, M. J., Hanaoka, Y., Kim, M. K., Meershoek-Klein-Kranenbarg, E., Kuroyanagi, H., Maas, M., Martling, A., Moore, J., Nieuwenhuijzen, G. A., Oh, S. N., Roodbeen, S., Sammour, T., Schaap, D., Solomon, M. J., Thomas, M., Tomizawa, K., van der Sande, M. E., Suzuki, C., van der Valk, M. J. M., Wells, T., Won, D. D., and Lateral Node Study Consortium

Abstract

PurposeImprovements in magnetic resonance imaging (MRI), total mesorectal excision (TME) surgery, and the use of (chemo)radiotherapy ([C]RT) have improved local control of rectal cancer; however, we have been unable to eradicate local recurrence (LR). Even in the face of TME and negative resection margins (R0), a significant proportion of patients with enlarged lateral lymph nodes (LLNs) suffer from lateral LR (LLR). Japanese studies suggest that the addition of an LLN dissection (LLND) could reduce LLR. This multicenter pooled analysis aims to ascertain whether LLNs actually pose a problem and whether LLND results in fewer LLRs.Patients and MethodsData from 1,216 consecutive patients with cT3/T4 rectal cancers up to 8 cm from the anal verge who underwent surgery in a 5-year period were collected. LLND was performed in 142 patients (12%). MRIs were re-evaluated with a standardized protocol to assess LLN features.ResultsOn pretreatment MRI, 703 patients (58%) had visible LLN, and 192 (16%) had a short axis of at least 7 mm. One hundred eight patients developed LR (5-year LR rate, 10.0%), of which 59 (54%) were LLRs (5-year LLR rate, 5.5%). After multivariable analyses, LLNs with a short axis of at least 7 mm resulted in a significantly higher risk of LLR (hazard ratio, 2.060; P = .045) compared with LLNs of less than 7 mm. In patients with LLNs at least 7 mm, (C)RT plus TME plus LLND resulted in a 5-year LLR of 5.7%, which was significantly lower than that in patients who underwent (C)RT plus TME (5-year LLR, 19.5%; P = .042).ConclusionLLR is still a significant problem after (C)RT plus TME in LLNs with a short axis at least 7 mm on pretreatment MRI. The addition of LLND results in a significantly lower LLR rate.

Published
2019

5. Staging laparoscopy with ultrasound and near-infrared fluorescence imaging to detect occult metastases of pancreatic and periampullary cancer

Author

Handgraaf, H. J. M., primary, Sibinga Mulder, B. G., additional, Shahbazi Feshtali, S., additional, Boogerd, L. S. F., additional, van der Valk, M. J. M., additional, Fariña Sarasqueta, A., additional, Swijnenburg, R. J., additional, Bonsing, B. A., additional, Vahrmeijer, A. L., additional, and Mieog, J. S. D., additional

Published
2018
Full Text
View/download PDF

6. Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue.

Author

Boogerd, L. S. F., Vuijk, F. A., Hoogstins, C. E. S., Handgraaf, H. J. M., van der Valk, M. J. M., Kuppen, P. J. K., Sier, C. F. M., van de Velde, C. J. H., Burggraaf, J., Fariña-Sarasqueta, A., and Vahrmeijer, Alexander L.

Subjects
TUMOR antigens, IMMUNITY, RECTAL cancer, PANCREATIC cancer, CARCINOEMBRYONIC antigen, CANCER patients
Abstract

Carcinoembryonic antigen (CEA)-targeted imaging and therapeutic agents are being tested in clinical trials. If CEA overexpression in malignant tissue corresponds with elevated serum CEA, serum CEA could assist in selecting patients who may benefit from CEA-targeted agents. This study aims to assess the relationship between serum CEA and CEA expression in pancreatic (n = 20) and rectal cancer tissues (n = 35) using histopathology. According to local laboratory standards, a serum CEA >3 ng/mL was considered elevated. In pancreatic cancer patients a significant correlation between serum CEA and percentage of CEA-expressing tumor cells was observed (P = .04, ρ = .47). All 6 patients with homogeneous CEA expression in the tumor had a serum CEA >3 ng/mL. Most rectal cancer tissues (32/35) showed homogeneous CEA expression, independent of serum CEA levels. This study suggests that selection of pancreatic cancer patients for CEA-targeted agents via serum CEA appears adequate. For selection of rectal cancer patients, serum CEA levels are not informative. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results